Stevanato Group S.p.A., a global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, has entered a collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company. The collaboration will enable Stevanato Group to add cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) PFS to its existing portfolio of solutions. 
 
By integrating Transcoject’s technological know-how with Stevanato Group’s capabilities and expertise in drug containment solutions and manufacturing, Stevanato Group will be able to offer pre-fillable syringes in glass and in both COP and COC polymers. The new syringe solutions, Nexa Flex, will be unveiled at the Pharmapack Europe conference in Paris, France, on February 1-2, 2023, at booth no. F46.
 
COP and COC pre-fillable syringes can be used in a wide range of applications, including sensitive biologics, mRNA vaccines, and hyaluronic acid-based drugs. The products’ versatility and customizability can make them ideal for meeting many compliance requirements, and they can be integrated into existing fill and finish lines.  
 
“The addition of COP and COC pre-fillable syringes will uniquely position Stevanato Group to be able to offer both COC, COP and glass options in the market, empowering customers to select the best-suited solution to fit their needs from multiple options,” said Mauro Stocchi, Chief Business Officer at Stevanato Group. “This is a testament to Stevanato Group’s focus on meeting market needs through an integrated and comprehensive portfolio of drug delivery solutions”. 
 
The technology is intended to enable a broad range of format options from 0.5ml to 200ml, making it adaptable to customers’ specific requirements. Stevanato Group expects the technology to be ready in 2025 with a first validated product for Luer Lock PFS. In the interim, Transcoject will support customers by providing sampling and the companies plan to use their current capacity to meet demand. A staked-needle PFS version is expected to be launched in the following years. 
 
“With this cooperation we combine the strengths of the two companies by bringing together complementary fields of technologies. We thereby intend to strengthen agility and flexibility in terms of customers benefit. In addition, we expect this collaboration to foster innovation and increase value for our customers. I believe this partnership will strengthen our ability to offer our customers outstanding pharma packaging solutions”, emphasized Dr. Christian von Falkenhausen, CEO of Transcoject GmbH.